Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8720842 | 1.00 | MEN1 (0.39) | MEN1KMT2AL3MBTL1TMEM97SIGMAR1 | |
| SCHEMBL7154934 | 0.91 | MEN1 (0.41) | MEN1KMT2AL3MBTL1TMEM97SIGMAR1 | |
| SCHEMBL11281689 | 0.85 | L3MBTL1 (0.50) | KMT2AL3MBTL1TMEM97SIGMAR1 | |
| SCHEMBL30380734 | 0.84 | CA1 (0.36) | L3MBTL1TMEM97SIGMAR1GSTP1 | |
| SCHEMBL13933149 | 0.84 | CA1 (0.36) | L3MBTL1TMEM97SIGMAR1GSTP1 | |
| SCHEMBL10586638 | 0.84 | CA1 (0.36) | L3MBTL1TMEM97SIGMAR1GSTP1 | |
| SCHEMBL10574146 | 0.84 | CA1 (0.36) | L3MBTL1TMEM97SIGMAR1GSTP1 | |
| SCHEMBL6567769 | 0.81 | L3MBTL1 (0.39) | MEN1KMT2AL3MBTL1TMEM97SIGMAR1 | |
| SCHEMBL10831460 | 0.81 | L3MBTL1 (0.39) | MEN1KMT2AL3MBTL1TMEM97SIGMAR1 | |
| SCHEMBL7152906 | 0.80 | SSTR1 (0.42) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036659-A1 | METHOD OF DEUTERATING BENZYL-POSITION IN -O-BENZYL GROUP | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036659-A1 | METHOD OF DEUTERATING BENZYL-POSITION IN -O-BENZYL GROUP | DBH, BRD4, BRD3 | MEN1 1558/4885KMT2A 747/4885L3MBTL1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.